No reliable current consensus is established here, so the cleanest anchor is the prior quarter: adjusted net investment income per share rose to $0.37 from $0.22, while the base dividend stayed at $0.32 and a $0.03 supplemental dividend was declared. That is a meaningful earnings improvement, but the supplemental payout follows the company's existing distribution framework rather than representing a new change in policy. (Quarterly Highlights; Selected Financial Highlights; Endnote 5)
| Measure | Q2 2026 | Q1 2026 | Read-through |
|---|---|---|---|
| Adjusted net investment income per share | $0.37 | $0.22 | Higher (Selected Financial Highlights) |
| Net investment income per share | $0.38 | $0.22 | Higher (Selected Financial Highlights) |
| Net investment income after taxes | $42.2 million | $24.8 million | Higher (Selected Financial Highlights) |
| Net realized and unrealized gains (losses) | $(18.6) million | $(38.4) million | Smaller loss, still negative (Selected Financial Highlights) |
| NAV per share | $12.06 | $12.17 | Down 0.9% (Quarterly Highlights) |
| Non-accruals at fair value | 2.9% | 3.2% | Improved (Portfolio Summary) |
| Non-accruals at amortized cost | 5.0% | 4.7% | Worsened (Portfolio Summary) |
| Ending net debt-to-equity | 1.35x | 1.37x | Slightly lower (Selected Financial Highlights) |
The income rebound was real but partly driven by lower incentive fees and restored accruals, not broad portfolio growth. Total investment income increased to $83.7 million from $78.8 million, while expenses fell to $40.7 million from $53.0 million, primarily because incentive fees dropped to zero for the quarter. Management also cited investments returning to accrual status. That supports near-term distribution coverage, but it is less durable than growth driven by stronger originations or higher portfolio yields. (Selected Financial Highlights; Consolidated Statements of Operations)
Credit trends remain the main offset. Fair-value non-accruals improved to 2.9% from 3.2%, and Thrasio returned to accrual status, but amortized-cost non-accruals increased to 5.0% from 4.7%, with two investments newly placed on non-accrual. Portfolio leverage also rose to 6.2x from 5.9x at December 31, 2025, while weighted-average yield at amortized cost declined to 9.5% from 9.9%. The better fair-value headline therefore overstates the improvement in underlying credit health. (Quarterly Highlights; Portfolio Summary)
The balance sheet is modestly safer, but NAV still absorbed another loss. Net debt-to-equity eased to 1.35x from 1.37x, and management said it fell below the 1.25x target by August 6 after repayments and sales. Even so, NAV declined to $12.06 from $12.17, or $12.03 after the declared supplemental dividend, while net realized and unrealized losses remained $18.6 million. Overall, the filing is better on current income and liquidity than the prior quarter, but the NAV erosion and mixed non-accrual trends keep the read from being clearly positive. (Quarterly Highlights; Selected Financial Highlights; Liquidity and Capital Resources)
Read the original 8-K on SEC EDGAR ↗